Chandra Tushar, Mohan Suyash
*Department of Radiology, Nemours Children's Hospital, Orlando, FL ‡Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA.
Top Magn Reson Imaging. 2016 Aug;25(4):151-6. doi: 10.1097/RMR.0000000000000094.
Magnetic resonance (MR) contrast agents have been widely used over the last 3 decades in routine clinical practice. Paul Lauterbur recognized the presence of these contrast agents, which act as paramagnetic catalysts that accelerate the T1 relaxation process. The first MR contrast agent to be approved for clinical use was in 1988, and since then, it is estimated that 200 million doses have been administered worldwide. These contrast agents have diverse clinical as well as research applications, involving almost all the body organs. This review will cover some existing as well as many new applications that have emerged over the last few decades. MR imaging now has the potential of being used to monitor enzymatic activity, gene expression, metal ion homeostasis, and cell death in vivo. In future, newer contrast agents will develop and become commercially available, expanding the current clinical applications of MR contrast media.
在过去三十年中,磁共振(MR)造影剂已在常规临床实践中广泛应用。保罗·劳特布尔发现了这些造影剂的存在,它们作为顺磁性催化剂,加速T1弛豫过程。1988年,第一种被批准用于临床的MR造影剂问世,自那时起,据估计全球已施用了2亿剂。这些造影剂具有多样的临床和研究应用,几乎涉及身体所有器官。本综述将涵盖过去几十年中出现的一些现有以及许多新应用。目前,磁共振成像有潜力用于监测体内的酶活性、基因表达、金属离子稳态和细胞死亡。未来,将开发出更新的造影剂并投入商业使用,从而扩大MR造影剂目前的临床应用范围。